instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Not applicable. The story presented the outcome of 472 obese individuals and examined in more detail those who were able, on average, to loss 14 pounds over a period of 26 weeks. The story did not provide any insight as to whether this amount of weight loss resulted in any health improvement in the obese individuals who were studied. So the true benefit – the true significance of the potential benefit – was not explained. Further – while the study found that those who got an adequate amount of sleep were among the cohort of individuals who were found to lose the most weight, the story did not explicitly point out that the study does not inform us about whether enforced hours of sleep would impact weight loss and weight loss management. So, again, the headline, the story’s first sentence, and the call to action by the researcher were not balanced. The story was reporting on the impact of getting adequate amounts of sleep on weight loss. While there was no overt discussion of the harm of obtaining adequate amounts of sleep, there doesn’t appear to be any harm involved in adequate sleep. Similar to the LA Times story we reviewed on the same study, this story did not challenge researchers’ comments that went too far in promoting a call to action based on one observational study – a study that can’t prove cause and effect. Its opening sentence is an example of that flaw:  “If you’re looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list…” Later, it didn’t challenge a researcher when he said, “If you want to lose weight, things that will help you include reducing stress and getting the right amount of sleep.”  That’s pushing the limits of what one can conclude based on one observational study and the story should have explained that limitation. Toward the end, in describing another study, it started in a good direction by explaining that conclusions “should be considered preliminary until published in a peer-reviewed journal.”  Actually, they should be considered preliminary because they were based on analysis of just 26 people. They should be considered to have evaded full scrutiny by expert colleagues until published in a peer-reviewed journal. Just because work has not been peer-reviewed does not make it preliminary. The intent, we think, was correct. But the explanation – the limitation – was not defined appropriately. The story did not engage in overt disease mongering. This story included expert quotes and also some insight from the results of a recently presented study. One of the strengths of this story in comparison with its shorter LA Times competition is the context it provided, much of it from an independent expert who said: “People who are healthy and vital tend to be healthy and vital not because of any one factor, but because of many. And the factors that promote health — eating well, being active, not smoking, sleeping enough, controlling stress, to name a few –promote all aspects of health. …The important message is that weight loss should not be looked at with tunnel vision. … This study encourages weight loss in a more holistic context.” Not applicable. The story was framed as taking a broader perspective when contemplating weight loss and including other lifestyle factors which can affect food intake and exercise. Better than its LA Times competition, at least this story nodded in the direction of one other recent study on sleep and weight, thereby conveying that the newer study is not the only research on this topic. It’s clear that the story did not rely solely on a news release.
answer:
Less Stress, Better Sleep May Help You Lose Weight


question:
"At a minimum, the reporter could have found out how much the master used in the study typically charges and how much the DVD costs. Still, unlike most of the stories, this reporter did write, ""Dr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy."" The story presents the evidence in relative terms. It would have been nice to see the absolute numbers. Still, it’s easy to calculate roughly what one third of 33 would be and one sixth would be. Essentially about 11 people stopped taking drugs after tai chi, and 5 or 6 stopped using other therapies. That’s not a huge difference, but, because there was any improvement, the researchers and the journal were understandably curious and hoping the study might spark more research. A big point of the story is that tai chi would be a much less onerous therapy with no harmful side effects. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study’s adverse events registry. The journal article on which the story is based clearly discussed this. The story makes it clear early that the study is small and that more research would be needed in order to recommend tai chi as a therapy. There is no disease mongering and the description of the syndrome is the best of the five stories we reviewed. Most of the quotes in the story are from people not affiliated with the study. The story talks about how the study compared different alternatives, and it mentions, at least in passing, several other therapies. The story makes it clear that there are multiple versions of tai chi. It could have been more clear about how widely available it might be, especially in sparsely populated areas. The story says, ""Recent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis. But not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches."" This is all important context, succinctly presented. This story shows that you can pull together a lot of information and still keep the story tight. The story is very well reported and goes well beyond the original study, the editorial and any supporting materials. We were unable to locate a press release about the study."
answer:
Tai Chi Reported to Ease Fibromyalgia


question:
EpiPens deliver potentially lifesaving doses of the generic drug epinephrine, via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction. “We are shipping product. Currently there is no shortage in the U.S.,” said Steve Danehy, a spokesman for Pfizer Inc (PFE.N), which produces the global supply of EpiPens for Mylan out of a single facility near St. Louis, Missouri. Mylan is in charge of managing allocation of the EpiPen supply, Danehy said in an email to Reuters. It was not immediately clear why Canada and the UK would be subject to a shortage at this time. A Mylan spokeswoman was not available for comment. Mylan’s EpiPen sales practices in the United States sparked public outrage in 2016 as consumers saw the price for a pack of two auto-injectors rise sixfold to $600 in less than a decade, making the devices unaffordable for a growing number of families. Since then, the company has launched a generic version of EpiPen for half the price, though the U.S. market is still the most lucrative. Meridian Medical Technologies Inc, the unit of Pfizer that manufactures EpiPens, has been hit by a series of manufacturing problems. In March 2017, Mylan recalled tens of thousands of devices after complaints that some had failed to activate. In September, Meridian received a warning letter from the U.S. Food and Drug Administration. The FDA said Meridian had failed to thoroughly investigate product failures, including EpiPen products that were associated with patient deaths and severe illnesses. It said the company failed to take corrective actions until FDA’s inspection. At the time, Mylan said it did not anticipate any impact on EpiPen supply based on the warning letter. But on Thursday, Pfizer Canada said it was “experiencing supply constraints” for EpiPens used by both adults and children “due to delays at the manufacturing facility,” as well as problems in sourcing a component for the device from an outside supplier. There are no alternatives on the market in Canada, federal health officials there said. They advised patients and caregivers to use expired EpiPens in an emergency if they have nothing else on hand, and then call 911. “Pfizer understands and regrets the challenges that these ongoing supply constraints pose to patients and the healthcare community,” the company said in a statement on its website. On Friday, the UK website for EpiPen notified consumers of “intermittent supply constraints” for the adult injector. It said the next shipment to EpiPen’s distributor in the country was expected toward the end of April. Mylan’s revenue from EpiPen dropped sharply over the last year due to increased competition, the launch of its own cheaper generic and higher rebates that it has had to pay to as a result of a settlement for overcharging the U.S. government.
answer:

EpiPen shortages seen in Canada, UK but U.S. supply intact.